82 related articles for article (PubMed ID: 18089885)
1. Erlotinib in pancreatic cancer: are tumor cells the (only) target?
Normanno N; De Luca A
J Clin Oncol; 2007 Dec; 25(36):5836-7. PubMed ID: 18089885
[No Abstract] [Full Text] [Related]
2. [Erlotinib, sunitinib, and everolimus].
Takahashi M
Nihon Rinsho; 2015 Mar; 73 Suppl 3():409-13. PubMed ID: 25857058
[No Abstract] [Full Text] [Related]
3. Erlotinib hydrochloride.
Minna JD; Dowell J
Nat Rev Drug Discov; 2005 May; Suppl():S14-5. PubMed ID: 15962526
[TBL] [Abstract][Full Text] [Related]
4. Does erlotinib restore chemosensitivity to chemotherapy in pancreatic cancer? A case series.
Saif MW
Anticancer Res; 2011 Mar; 31(3):1039-42. PubMed ID: 21498735
[TBL] [Abstract][Full Text] [Related]
5. Erlotinib.
Steins M; Thomas M; Geissler M
Recent Results Cancer Res; 2014; 201():109-23. PubMed ID: 24756788
[TBL] [Abstract][Full Text] [Related]
6. Molecularly targeted therapies in metastatic pancreatic cancer: a systematic review.
Zagouri F; Sergentanis TN; Chrysikos D; Zografos CG; Papadimitriou CA; Dimopoulos MA; Filipits M; Bartsch R
Pancreas; 2013 Jul; 42(5):760-73. PubMed ID: 23774698
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer.
Welch SA; Moore MJ
Future Oncol; 2007 Jun; 3(3):247-54. PubMed ID: 17547518
[TBL] [Abstract][Full Text] [Related]
8. Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: is timing important?
Riely GJ; Pao W
Cancer Biol Ther; 2005 Oct; 4(10):1096-7. PubMed ID: 16294020
[No Abstract] [Full Text] [Related]
9. Targeting of epidermal growth factor receptor in patients affected by biliary tract carcinoma.
Leone F; Pignochino Y; Cavalloni G; Aglietta M
J Clin Oncol; 2007 Mar; 25(9):1145; author reply 1145-6. PubMed ID: 17369582
[No Abstract] [Full Text] [Related]
10. The role of the epidermal growth factor receptor in breast cancer.
Chan SK; Hill ME; Gullick WJ
J Mammary Gland Biol Neoplasia; 2006 Jan; 11(1):3-11. PubMed ID: 16947082
[TBL] [Abstract][Full Text] [Related]
11. Is there a role for the irreversible epidermal growth factor receptor inhibitor EKB-569 in the treatment of cancer? A mutation-driven question.
Baselga J
J Clin Oncol; 2006 May; 24(15):2225-6. PubMed ID: 16710019
[No Abstract] [Full Text] [Related]
12. Will lung cancer targeting hit its mark?
Hampton T
JAMA; 2005 Apr; 293(16):1963-4. PubMed ID: 15855415
[No Abstract] [Full Text] [Related]
13. [Epidermal growth factor receptor family and targeted anticancer therapy].
Liu TH
Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):577-9. PubMed ID: 17134561
[No Abstract] [Full Text] [Related]
14. Erlotinib (Tarceva): an update on the clinical trial program.
Herbst RS
Semin Oncol; 2003 Jun; 30(3 Suppl 7):34-46. PubMed ID: 12840799
[TBL] [Abstract][Full Text] [Related]
15. Combining epidermal growth factor receptor inhibitors and radiation therapy in pancreatic cancer: small step or giant leap?
Chang BW; Saif MW
JOP; 2009 May; 10(3):231-6. PubMed ID: 19454812
[TBL] [Abstract][Full Text] [Related]
16. Challenges and opportunities for Erlotinib (Tarceva): what does the future hold?
Hortobagyi GN; Sauter G
Semin Oncol; 2003 Jun; 30(3 Suppl 7):47-53. PubMed ID: 12840800
[TBL] [Abstract][Full Text] [Related]
17. [Report from a small registry-permetrexed, tarceva and yondelis].
Pochop L; Hejduk K
Klin Onkol; 2013; 26(1):53-4. PubMed ID: 23607142
[No Abstract] [Full Text] [Related]
18. Targeting the epidermal growth factor receptor in colorectal carcinoma.
Kurtin SE
Cancer Nurs; 2007; 30(4 Suppl 1):S1-9. PubMed ID: 17666985
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
20. Radiation recall gastritis secondary to erlotinib in a patient with pancreatic cancer.
Graziani C; Hegde S; Saif MW
Anticancer Res; 2014 Dec; 34(12):7339-43. PubMed ID: 25503169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
